Stocks and Investing
Stocks and Investing
Wed, March 29, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Shibutani Maintained (BNTX) at Hold with Decreased Target to $140 on, Mar 28th, 2023
Chris Shibutani of Goldman Sachs, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $156 to $140 on, Mar 28th, 2023.
Chris has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $142 on, Wednesday, February 8th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $216 on, Tuesday, January 24th, 2023
This is the rating of the analyst that currently disagrees with Chris
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $210 on, Thursday, March 23rd, 2023
Contributing Sources